ADDED
As of February 13, 2026, the registrant had 87,814,027 shares of common stock, $0.0001 par value per share, outstanding.
This number does not include 875,135 shares of common stock issuable upon the exercise of pre-funded warrants outstanding as of February 13, 2026 (which are immediately exercisable at an exercise price of $0.0001 per share of common stock, subject to beneficial ownership limitations).
(Gilead), our Clinical Trial Collaboration and Supply Agreements with Pfizer Inc.
(Pfizer), our License Agreement with Novartis, our Option and License Agreement with Cancer Research Technologies Ltd.
and the University of Manchester, our Option and License Agreement with Biocytogen ii Pharmaceuticals (Beijing) Co.
(Biocytogen), our License Agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Furthermore, results of earlier studies and trials may not be predictive of future trial results; We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being developed and due to competition for such patients with other product candidates under development.
Most of our competitors have significantly greater resources than we do and we may not be able to successfully compete; If we fail to attract and retain senior management and key scientific and commercial personnel, our business may be materially and adversely affected; We rely on third parties for the manufacture of our product candidates for preclinical and clinical development and expect to continue to do so for the foreseeable future, including for any future approved commercial products.
This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts; Our success depends on our ability to obtain and maintain protection for our intellectual property and our proprietary technologies and to avoid infringing the rights of others; and Our stock price may be volatile and you may not be able to resell shares of our common stock at or above the price you paid.
Company Overview We are a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.
REMOVED
As of February 14, 2025, the registrant had 87,537,391 shares of common stock, $0.0001 par value per share, outstanding.
We have incurred significant losses since our inception, and we anticipate that we will iii continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability; We are early in our development efforts.
Furthermore, results of earlier studies and trials may not be predictive of future trial results; We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being developed.
This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts; We face significant competition in an environment of rapid technological and scientific change, and our failure to effectively compete may prevent us from achieving significant market penetration.
Most of our competitors have significantly greater resources than we do and we may not be able to successfully compete; If we fail to attract and retain senior management and key scientific and commercial personnel, our business may be materially and adversely affected; Our success depends on our ability to obtain and maintain protection for our intellectual property and our proprietary technologies and to avoid infringing the rights of others; and Our stock price may be volatile and you may not be able to resell shares of our common stock at or above the price you paid.
Company Overview We are a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
We are applying these capabilities and approach to develop a robust pipeline in precision medicine oncology.
Pipeline Overview and Program Goals Our clinical pipeline includes six potential first-in-class clinical-stage product candidates darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase).
We own or control all commercial rights of three of these product candidates: darovasertib, IDE397, and IDE161, and own or control all commercial rights outside of greater China for IDE849.
We are also advancing several development candidates, including IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor for which we are targeting an investigational new drug, or IND, filing in mid-year 2025; IDE034, a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload bispecific antibody drug conjugate, or BsADC, program for which we are targeting an IND filing in the second half of 2025; and IDE251, a potential first-in-class KAT6/7 dual inhibitor program for which we are targeting an IND filing in the second half of 2025.